Arca
Skip to content
Tools
Tools

CSF2: Granulocyte-macrophage colony-stimulating factor

Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. .

  • Drugs that act on it: 6
  • Approved: 0
  • In phases 1 to 3: 6
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on CSF2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 5
  • Other 1

Approved0

    Phase 33

    • Lenzilumab
    • Otilimab
    • Pexastimogene devacirepvec

    Phase 23

    • Plonmarlimab
    • Gimsilumab
    • Namilumab

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Humanigen, Inc.117%
      • Jennerex Biotherapeutics117%
      • Kinevant Sciences GmbH117%
      • TJ Biopharma Co., Ltd.117%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 6 act as: Granulocyte-macrophage colony-stimulating factor inhibitor; the rest name their own mechanism.
      LenzilumabPhase 3Humanigen, Inc.AntibodyInhibitor0
      OtilimabPhase 3GSKAntibodyInhibitor0
      Pexastimogene devacirepvecPhase 3Jennerex BiotherapeuticsGeneVaccine antigenGranulocyte-macrophage colony-stimulating factor vaccine antigen0
      PlonmarlimabPhase 2TJ Biopharma Co., Ltd.AntibodyAntagonistGranulocyte-macrophage colony-stimulating factor antagonist2
      GimsilumabPhase 2Kinevant Sciences GmbHAntibodyInhibitor0
      NamilumabPhase 2Takeda Pharmaceuticals USAAntibodyInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Hypothyroidism0.34
      • Neurodegenerative disease0.29
      • Atopic eczema0.28
      • Nasal cavity polyp0.21
      • Lower respiratory tract disorder0.19

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712955, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P04141, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.